The third-generation nanopore sequencing raised by Oxford Nanopore Technologies shows potential in developing low-cost, high-performance clinical sequencing-based assays with quick turnaround times to provide IDH mutation detections in FFPE tumor tissue [13]. The gene discussed is IDH2; the disease is neoplasm.